Compare AbbVie Inc (ABBV) vs iShares Russell 2000 ETF (IWM) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

IWM, the iShares Russell 2000 ETF, trades at $301.53, up 1.11% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks US small-cap stocks, which have shown strong performance in 2026, though financial ratios are not applicable as it is a fund. Recent news highlights institutional inflows and small-cap outperformance versus large caps.

Outlook for IWM is positive due to small-cap strength and institutional support, but risks include higher volatility and competition from alternative ETFs. The bullish trend may continue if economic conditions favor small companies, though overbought RSI levels suggest potential near-term pullbacks.